Company intelligence / Profile preview

Brain Trust Bio

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Brain Trust Bio is a clinical-stage biotechnology company focused on developing innovative treatments for central nervous system (CNS) disorders. The company utilizes its proprietary Continuous Intrathecal Drug Delivery (CIDD) platform to deliver therapeutics directly into the cerebrospinal fluid, bypassing the blood-brain barrier to enhance efficacy and reduce systemic toxicity. Its lead program, BTB-001, is a novel formulation of riluzole being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS). By optimizing drug concentration at the site of disease, Brain Trust Bio aims to significantly improve outcomes for patients with neurodegenerative conditions.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Brain Trust Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brain Trust Bio.

Explore the full profile